Abstract：With the advent of anti-vascular endothelial growth factor drugs, the treatment of neovascular senile macular degeneration has been greatly developed. However, there are still some patients who have poor effect after long-term treatment with the same drug, which may be related to drug resistance and rapid drug resistance response. At this time, drug replacement is a feasible option. As a representative of fusion protein drugs, Aphercept has the advantages of high affinity binding to vascular endothelial growth factor and multiple targets. This article reviews the current research status of switching to Aphercept in patients with refractory neovascular senile macular degeneration, in order to provide ideas for the treatment of this disease.
文艳 彭惠. 难治性新生血管性老年性黄斑变性患者改用阿柏西普的研究进展[J]. 中国医药导报, 2022, 19(30): 41-44,49.
WEN Yan PENG Hui. Research progress in switching to Aphercept in patients with refractory neovascular senile macular degeneration. 中国医药导报, 2022, 19(30): 41-44,49.
[1] Lipecz A，Miller L，Kovacs I，et al. Microvascular contributions to age-related macular degeneration（AMD）：from mechanisms of choriocapillaris aging to novel interventions [J]. Geroscience，2019，41（6）：813-845.
[2] 张敬法，赵珍珍.湿性年龄相关性黄斑变性发病机制及治疗[J].眼科新进展，2022，42（2）：85-98.
[3] Ehlken C，Jungmann S，B?觟hringer D，et al. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD [J]. Eye（Lond），2014，28（5）：538-545.
[4] Binder S. Loss of reactivity in intravitreal anti-VEGF therapy：tachyphylaxis or tolerance？[J]. Br J Ophthalmol，2012，96（1）：1-2.
[5] Broadhead GK，Hong T，Chang AA. Treating the untreatable patient：current options for the management of treatment-resistant neovascular age-related macular degeneration [J]. Acta Ophthalmol，2014，92（8）：713-723.
[6] Amoaku WM，Chakravarthy U，Gale R，et al. Defining response to anti-VEGF therapies in neovascular AMD [J]. Eye （Lond），2015，29（6）：721-731.
[7] Zuber-Laskawiec K，Kubicka-Trzaska A，Karska-Basta I，et al. Non-responsiveness and tachyphylaxis to anti-vascular endothelial growth factor treatment in naive patients with exudative age-related macular degeneration [J]. J Physiol Pharmacol，2019，70（5）：779-785.
[8] Yang S，Zhao J，Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration：a comprehensive review [J]. Drug Des Devel Ther，2016，10：1857- 1867.
[9] 付燕，张月玲，王丽英，等.湿性年龄相关性黄斑变性患者抗VEGF治疗无效的因素分析和视功能预后[J].眼科新进展，2021，41（3）：254-258.
[10] 程子芳，王雨生，王海燕，等.抗血管内皮生长因子治疗湿性年龄相关性黄斑变性的效果及复发因素分析[J].中华实验眼科杂志，2021，39（1）：20-26.
[11] Comparison of Age-related Macular Degeneration Treatments Trials（CATT）Research Group，Writing C，Martin DF，et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration：Two-Year results [J]. Ophthalmology，2020，127（4S）：S135-S145.
[12] Spooner K，Hong T，Nair R，et al. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration [J]. Acta Ophthalmol，2019，97（5）：e706-e712.
[13] Razavi S，Kodjikian L，Giocanti-Aurégan A，et al. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration [J]. BMC Ophthalmol，2021，21（1）：90.
[14] Spooner K，Hong T，Wijeyakumar W，et al. Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration：a systematic review with meta-analysis [J]. Clin Ophthalmol，2017，11：161-177.
[15] 邓凯予，叶娅，黄晓莉，等.阿柏西普初始治疗及换药治疗对渗出型老年性黄斑变性的短期疗效观察[J].中华眼底病杂志，2021，37（9）：687-692.
[16] Veritti D，Sarao V，Parravano MA，et al. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD：a prospective study [J]. Eur J Ophthalmol，2017，27（1）：74-79.
[17] Broadhead GK，Hong T，Zhu M，et al. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration [J]. Retina，2015，35（5）：975-981.
[18] Kim K，Kim ES，Kim Y，et al. OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION [J]. Retina，2019， 39（2）：303-313.
[19] Abri AK，Seidensticker F，Pielen A，et al. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography [J]. Lasers Surg Med，2016， 48（7）：668-677.
[20] Van Steenkiste C，Ribera J，Geerts A，et al. Inhibition of placental growth factor activity reduces the severity of fibrosis，inflammation，and portal hypertension in cirrhotic mice [J]. Hepatology，2011，53（5）：1629-1640.
[21] Woronkowicz M，Lightman S，Tomkins-Netzer O. The prognostic value of total macular external limiting membrane and ellipsoid zone damage for clinical outcome in treatment-resistant neovascular age-related macular degeneration [J]. Graefes Arch Clin Exp Ophthalmol，2020，258（11）：2373-2378.
[22] Oishi A，Tsujikawa A，Yamashiro K，et al. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome [J]. Am J Ophthalmol，2015，159（5）：853-60.e1.
[23] Roberts P，Mittermueller TJ，Montuoro A，et al. A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD [J]. Invest Ophthalmol Vis Sci，2014，55（10）：6623- 6630.
[24] Coscas F，Coscas G，Lupidi M，et al. Restoration of Outer Retinal Layers After Aflibercept Therapy in Exudative AMD：Prognostic Value [J]. Invest Ophthalmol Vis Sci，2015，56（6）：4129-4134.
[25] Elfandi S，Ooto S，Miyata M，et al. Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy：Comparison with Typical Neovascular Age-Related Macular Degeneration [J]. Clin Ophthalmol，2021，15：1539- 1549.
[26] Uji A，Murakami T，Nishijima K，et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema [J]. Am J Ophthalmol，2012，153：710-717.
[27] Abri AK，Pielen A，Framme C，et al. Correlation Between Hyperreflective Foci and Clinical Outcomes in Neovascular Age-Related Macular Degeneration After Switching to Aflibercept [J]. Invest Ophthalmol Vis Sci，2015，56（11）：6448-6455.
[28] Türksever C，Prünte C，Hatz K. Baseline Optical Coherence Tomography Findings as Outcome Predictors after Switching from Ranibizumab to Aflibercept in Neovascular Age-Related Macular Degeneration following a Treat- and-Extend Regimen [J]. Ophthalmologica，2017，238（3）：172-178.
[29] Husum YS，Moe MC，Bragadóttir R，et al. Switching to aflibercept versus continuing bevacizumab for treatment-resistant neovascular age-related macular degeneration：a one-year comparative observational study [J]. Acta Ophthalmol，2021，99（8）：e1354-e1359.
[30] Hamid MA，Abdelfattah NS，Salamzadeh J，et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab [J]. Int J Retina Vitreous，2021，7（1）：26.
[31] Lee CS，Kim AJ，Baughman D，et al. Visual acuity improvement when switching from ranibizumab to aflibercept is not sustained [J]. Retina，2018，38（5）：951-956.
[32] Koike N，Otsuji T，Tsumura A，et al. Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration [J]. Clin Ophthalmol，2019，13：1247-1251.
[33] Queguiner F，Bezirganyan K，Courjaret JC，et al. Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD：results of real life ELU study [J]. Int J Ophthalmol，2020，13（2）：252-256.
[34] J?覬rstad ?覫K，Faber RT，Moe MC. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol [J]. Acta Ophthalmol，2017，95（5）：460-463.
[35] Sarao V，Parravano M，Veritti D，et al. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY [J]. Retina，2016，36（4）：770-777.
[36] Zhu M，Wijeyakumar W，Syed AR，et al. Vision-related quality of Life：12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration [J]. Graefes Arch Clin Exp Ophthalmol，2017，255（3）：475-484.
京公网安备 11010502046598号